/K I L L K I L L K I L L -- Bristol-Myers Squibb Medical Imaging/

11.10.2006 – 09:01

Journalists and other readers should disregard the news release
"Bristol-Myers Squibb Medical Imaging Receives European Commission
Marketing Authorisation for Its Ultrasound Contrast Agent
LUMINITY(TM)  (perflutren lipid microsphere)" NYSE:BMY, issued
earlier today. The release  was issued prematurely by PR Newswire.

Contact:

Brian Henry, +33-1-58-83-69-38, brian.henry@bms.com, or Lili Gordon,
+1-617-733-7537, lili.gordon@bms.com, both of Bristol-Myers Squibb

Paramètres des cookies

/K I L L K I L L K I L L -- Bristol-Myers Squibb Medical Imaging/

Bristol-Myers Squibb Medical Imaging Receives European Commission Marketing Authorisation for Its Ultrasound Contrast Agent LUMINITY(TM) (perflutren lipid microsphere)